MDDLX | VIVIX | MDDLX / VIVIX | |
Total Expense Ratio | 0.94 | 0.04 | 2,350% |
Annual Report Gross Expense Ratio | 0.94 | 0.04 | 2,350% |
Fund Existence | 21 years | 27 years | - |
Gain YTD | 6.797 | 5.533 | 123% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 0 | 5000000 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 337M | 189B | 0% |
Annual Yield % from dividends | 1.62 | 2.19 | 74% |
Returns for 1 year | -15.97 | 11.47 | -139% |
Returns for 3 years | -7.63 | 34.30 | -22% |
Returns for 5 years | 17.43 | 78.98 | 22% |
Returns for 10 years | -17.60 | 113.38 | -16% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
CGFEX | 78.97 | 0.50 | +0.64% |
American Funds Growth Fund of Amer 529E | |||
JSCVX | 22.18 | N/A | N/A |
Janus Henderson Small Cap Value T | |||
JFNSX | 62.73 | N/A | N/A |
Janus Henderson Global Life Sciences S | |||
MSEEX | 25.24 | N/A | N/A |
Morgan Stanley Europe Opportunity C | |||
VILSX | 37.38 | -0.30 | -0.80% |
Value Line Select Growth Institutional |